53 research outputs found
Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor
The presence of different transcripts of a gene across samples can be
analysed by whole-transcriptome microarrays. Reproducing results from published
microarray data represents a challenge due to the vast amounts of data and the
large variety of pre-processing and filtering steps employed before the actual
analysis is carried out. To guarantee a firm basis for methodological
development where results with new methods are compared with previous results
it is crucial to ensure that all analyses are completely reproducible for other
researchers. We here give a detailed workflow on how to perform reproducible
analysis of the GeneChip Human Exon 1.0 ST Array at probe and probeset level
solely in R/Bioconductor, choosing packages based on their simplicity of use.
To exemplify the use of the proposed workflow we analyse differential splicing
and differential gene expression in a publicly available dataset using various
statistical methods. We believe this study will provide other researchers with
an easy way of accessing gene expression data at different annotation levels
and with the sufficient details needed for developing their own tools for
reproducible analysis of the GeneChip Human Exon 1.0 ST Array
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
BACKGROUND: Accurate adjustment for the amplification efficiency (AE) is an important part of real-time quantitative polymerase chain reaction (qPCR) experiments. The most commonly used correction strategy is to estimate the AE by dilution experiments and use this as a plug-in when efficiency correcting the ΔΔC(q). Currently, it is recommended to determine the AE with high precision as this plug-in approach does not account for the AE uncertainty, implicitly assuming an infinitely precise AE estimate. Determining the AE with such precision, however, requires tedious laboratory work and vast amounts of biological material. Violation of the assumption leads to overly optimistic standard errors of the ΔΔC(q), confidence intervals, and p-values which ultimately increase the type I error rate beyond the expected significance level. As qPCR is often used for validation it should be a high priority to account for the uncertainty of the AE estimate and thereby properly bounding the type I error rate and achieve the desired significance level. RESULTS: We suggest and benchmark different methods to obtain the standard error of the efficiency adjusted ΔΔC(q) using the statistical delta method, Monte Carlo integration, or bootstrapping. Our suggested methods are founded in a linear mixed effects model (LMM) framework, but the problem and ideas apply in all qPCR experiments. The methods and impact of the AE uncertainty are illustrated in three qPCR applications and a simulation study. In addition, we validate findings suggesting that MGST1 is differentially expressed between high and low abundance culture initiating cells in multiple myeloma and that microRNA-127 is differentially expressed between testicular and nodal lymphomas. CONCLUSIONS: We conclude, that the commonly used efficiency corrected quantities disregard the uncertainty of the AE, which can drastically impact the standard error and lead to increased false positive rates. Our suggestions show that it is possible to easily perform statistical inference of ΔΔC(q), whilst properly accounting for the AE uncertainty and better controlling the false positive rate
Quantification of reproducibility of microarray experiments by semi-parametric mixture models applied to the detection of differentially expressed genes in B-cell subpopulations
High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
Statistical Methods for Tracing the Molecular Origin of Treatment Resistance in Diffuse Large B-Cell Lymphoma
Expression data from malignant human B-cell cell lines
We used global gene expression profiles from human B-cell cell lines to generate gene expression signatures for prediction of response to the drugs cyclophosphamide, doxorubicin or vincristine. The signatures were validated in two publicly available clinical cohorts. Global gene expression data combined with dose response experiments for prediction of chemoresistanc
High Expression of CXCR4 Impairs Anti-CD20 Monoclonal Antibody (Rituximab)-Dependent Cytotoxicity in Diffuse Large B-Cell Lymphoma
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.
BACKGROUND: Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information. MATERIALS AND METHODS: Microarray based GEPs and a melphalan growth inhibition screen of 59 cancer cell lines were downloaded from the National Cancer Institute database. Equivalent data were generated for 18 B-cell cancer cell lines. Linear discriminant analyses (LDA), sparse partial least squares (SPLS) and pairwise comparisons of cell line data were used to build resistance signatures from both cell line panels. A melphalan resistance index was defined and estimated for each MM patient in a publicly available clinical data set and evaluated retrospectively by Cox proportional hazards and Kaplan-Meier survival analysis. PRINCIPAL FINDINGS: Both cell line panels performed well with respect to internal validation of the SPLS approach but only the B-cell panel was able to predict a significantly higher risk of relapse and death with increasing resistance index in the clinical data sets. The most sensitive and resistant cell lines, MOLP-2 and RPMI-8226 LR5, respectively, had high leverage, which suggests their differentially expressed genes to possess important predictive value. CONCLUSION: The present study presents a melphalan resistance index generated by analysis of a B-cell panel of cancer cell lines. However, the resistance index needs to be functionally validated and correlated to known MM biomarkers in independent data sets in order to better understand the mechanism underlying the preparedness to melphalan resistance
- …